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ABSTRACT
Small virus-derived interfering RNAs (viRNAs) play
an important role in antiviral defence in plants,
insects and nematodes by triggering the RNA inter-
ference (RNAi) pathway. The role of RNAi as an
antiviral defence mechanism in mammalian cells
has been obscure due to the lack of viRNA detec-
tion. Although viRNAs from different mammalian
viruses have recently been identified, their functions
and possible impact on viral replication remain
unknown. To identify viRNAs derived from HIV-1,
we used the extremely sensitive SOLiD
TM 3 Plus
System to analyse viRNA accumulation in
HIV-1-infected T lymphocytes. We detected
numerous small RNAs that correspond to the
HIV-1 RNA genome. The majority of these se-
quences have a positive polarity (98.1%) and could
be derived from miRNAs encoded by structured
segments of the HIV-1 RNA genome (vmiRNAs). A
small portion of the viRNAs is of negative polarity
and most of them are encoded within the 30-UTR,
which may represent viral siRNAs (vsiRNAs). The
identified vsiRNAs can potently repress HIV-1 pro-
duction, whereas suppression of the vsiRNAs by
antagomirs stimulate virus production. These
results suggest that HIV-1 triggers the production
of vsiRNAs and vmiRNAs to modulate cellular and/
or viral gene expression.
INTRODUCTION
Virus infection of plants, insects, nematodes and fungi
results in the production of virus-derived small interfering
RNAs (viRNA), which are processed from double-
stranded RNA (dsRNA) replication intermediates. These
viRNAs trigger the RNA interference (RNAi) pathway
and act as guides for the RNA-induced silencing
complex (RISC) which catalyses the sequence-speciﬁc
cleavage of the perfect complementary viral transcripts
(1–5). These viruses usually express RNA silencing sup-
pressors (RSSs) to counter this RNA-based antiviral
response (6). Although the RNAi machinery is well
conserved and functional in mammals, viRNAs could
not easily be detected in virus-infected cells of mammalian
origin (7). The large DNA viruses, mainly from the family
of the herpesviridae, encode multiple viRNAs that are
derived from structured single-stranded transcripts, and
thus represent virus-encoded miRNAs (vmiRNA), which
are believed to regulate the expression of speciﬁc viral and/
or cellular mRNAs (8–10). However, research failed to
detect virus-speciﬁc small RNAs in cells infected with
mammalian viruses, which is possibly due to extremely
low expression levels of the viRNAs.
Deep-sequencing technology can be used as a highly
sensitive method to study all kinds of small RNA species
in cells (10–13). The possibility to generate tens of
millions of sequence reads from a single sample makes
these methods effective tools for the discovery of uniden-
tiﬁed low-abundant regulatory RNAs (14). Recent deep-
sequencing studies showed that viRNAs do indeed accu-
mulate in virus-infected mammalian cells. Parameswaran
et al. (15) reported small virus-derived RNAs in cells
infected with Dengue virus, vesicular stomatitis virus,
polio virus, hepatitis C virus and West Nile virus.
The 454-sequencing technology also revealed that
transposon-speciﬁc siRNAs, so-called endo-siRNAs, are
produced in mouse oocytes to block transposon activ-
ity (16). Because retroviruses such as the human im-
munodeﬁciency virus type 1 (HIV-1) are related to
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DNA genome in the host cell DNA, it is likely that
HIV-1-speciﬁc viRNAs can be produced in infected
cells to regulate and possibly down-modulate virus repli-
cation. Indeed, Yeung et al. (17) reported the accumula-
tion of small RNAs in HIV-1-infected cells. In that
study, 454 sequencing of HIV-1-derived small RNAs
yielded only about 100 reads that map to the HIV-1
genome. Another study used the SOLiD deep-sequencing
technology, which was designed to be more sensitive than
454 sequencing (14). Cells were infected with a VSV-G
pseudotyped HIV-1 vector and the authors yielded 0.7%
sequences of viral origin, but half of these reads were
vector-derived GFP sequences (18). In this study, we
also used SOLiD sequencing to identify HIV-1-derived
small RNAs.
We performed small RNA cloning followed by ultra
deep sequencing using SOLiD
TM technology to analyze
small RNA species of  15–33nt in HIV-1-infected cells.
We identiﬁed 26000 HIV-1-derived small RNAs, which is
1% of the total small RNA population. The majority of
small RNAs are derived from cellular miRNAs, tRNAs
and ribosomal RNAs. A small portion of sequences cor-
respond to endogenous transposable elements. Although
small RNAs can be found throughout the plus-strand
HIV-1 RNA genome, several hot spots were identiﬁed.
In addition, a restricted set of speciﬁc minus-strand
viRNA were found. Collectively, these viRNAs represent
two types of virus-derived small RNAs that originate from
two distinct pathways (Figure 1). The vmiRNAs originate
from hairpin structures in the plus-strand viral transcript
that are processed by the RNAi machinery (Drosha,
Dicer). The vsiRNAs are likely produced by Dicer from
dsRNA formed between HIV-1 RNA and antisense tran-
scripts, which are made from an antisense promoter
located either within or downstream of the integrated
provirus. Further analyses of the identiﬁed HIV-1-
derived vmiRNAs revealed candidates that are functional
and we describe vsiRNAs that can inhibit virus
production.
MATERIAL AND METHODS
Virus infection
SupT1 suspension T cells were grown in Advanded
Rosewell Park Memorial Institute medium (Invitrogen,
Carlsbad, CA, USA) supplemented with L-glutamine,
1% fetal calf serum (FCS), penicillin (30U/ml) and
streptomycin (30mg/ml), in a humidiﬁed chamber at
37 C and 5% CO2. The full-length HIV-1 molecular
clone pLAI was described (19) and a doxycycline (dox)-
inducible HIV-1 variant, HIV-rtTA, was constructed pre-
viously (20). In HIV-rtTA, the Tat/TAR axis required for
transactivation of transcription is replaced by the
tet-operator/rtTA system for dox-inducible promoter
activity and virus replication. HIV-1 and HIV-rtTA
virus were produced by transfection of the respective mo-
lecular clones in 293T cells as described previously (21).
Virus was harvested from the transfected cultures 2 days
post infection. Virus production was measured by CA-p24
enzyme-linked immunosorbent assay (ELISA). SupT1
cells (20 10
6 cells) were infected with HIV-1 or the indu-
cible HIV-rtTA variant for subsequent SOLiD
sequencing. The latter culture received dox (1000ng/ml)
to drive viral gene expression. SupT1 cells infected with
HIV-1 reached a 60% infection grade as determined by
intracellular CA-p24 staining by FACS and HIV-rtTA
reached a 2% infection level. For FACS analysis,
2 10
6 cells are pelleted (4min, 4000rpm) and ﬁxated
for 5min at room temperature (RT) with 200ml 37% for-
maldehyde (stabilized with 10% methanol) diluted in
phosphate buffered saline. Next, cells are taken up in
FACS buffer (2% BSA/FCS in phosphate buffered
saline) and again pelleted. Supernatant was removed and
cells were stored at 4 C. The cells were washed with BD
Perm/Wash
TM buffer (BD Pharmingen) and stained for
minimally 30min at 4 C with RD1-conjugated mouse
monoclonal anti-CA-p24 antibody diluted (1:100) in BD
Perm/Wash
TM buffer. Excess antibody was removed by
washing the cells with BD Perm/Wash
TM buffer and the
cells were resuspended in FACS buffer. Cells were
analyzed on a BD FACSCanto II ﬂow cytometer with
Figure 1. Origin of HIV-1 viRNAs. Two main classes of viRNAs can be produced by HIV-1 that we termed vmiRNAs and vsiRNAs. The
vmiRNAs originate from structured regions in the viral RNA genome that trigger Drosha/Dicer processing. The vsiRNAs are produced from
extended dsRNA formed by HIV-1 RNA and antisense RNA made by convergent transcription of the HIV-1 genome. These antisense transcripts are
made from a promoter in the viral genome or the ﬂanking cellular genes. Promoter elements are indicated by arrows. Putative polyadenylation
signals (pA) are indicated (54). The dsRNA is marked by a gray box.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 415BD FACSDiva Software v6.1.2 (BD biosciences, San Jose,
CA, USA). Uninfected SupT1 cells were used as negative
control. Uninfected SupT1 cells treated with dox served as
an additional control. To ensure single round infection,
the fusion inhibitor T1249 was added (400nM) to the
media 24h post infection. Total RNA was isolated 48h
post infection.
Small RNA library preparation and emulsion PCR for
SOLiD sequencing
Total RNA was isolated from (HIV-1 or HIV-rtTA)-
infected SupT1 cells and uninfected control cells using
the mirVana miRNA isolation kit (Ambion). To purify
the small RNA population, a denaturing PAGE gel
(6%) was used for size fractionation. The  15–40nt
RNA fragments were eluted and subsequently used to
create a small RNA library that is compatible with the
SOLiD-sequencing platform. We used the SOLiD
TM
Small RNA Expression Kit in which small RNAs are
hybridized and ligated to adaptors. Next, the small RNA
population with ligated adaptors is reverse transcribed
into cDNA with a subsequent RNase H treatment to
remove the RNA template. The cDNA library is ampliﬁed
in 13–15 cycles of Polymerase Chain Reaction (PCR) with
the primer set supplied in the kit. To concentrate samples
and remove PCR by-products from the ampliﬁed cDNA
library, PCR products of  105–150bp that correspond to
the small RNA population were isolated from PAGE gel.
Samples are now ready for emulsion PCR (ePCR),
which was performed according to the manufacturer’s in-
structions (Applied biosystems, SOLiD System 3.0 user
guide). The sequence templates were attached to beads
and clonal bead populations were prepared in
microreactors containing template, PCR reaction compo-
nents, beads and primers. After ePCR, the templates are
denatured and bead enrichment is performed for the
templated beads, which was required to isolate templated
beads from non-amplifying or poorly amplifying beads.
Finally, the template on the selected beads was 30
modiﬁed by Terminal Transferase to allow covalent
bonding to a glass slide and subsequently sequenced in
the SOLiD analyzer (Applied Biosystems).
Bioinformatics
Analysis of the SOLiD colorspace reads was performed
with rna2map v0.5.0, also known as the ‘small RNA
pipeline’ (SOLiD software development community).
First, small RNA sequences were selected that mapped
on the HIV-1 genome (HIV-1 wild-type isolate LAI or
the HIV-rtTA construct was used as template). All
HIV-1 genome mapping was done with a 15nt seeding
step length, allowing 0 mismatches, whereas after the
seeding step mismatches and bulges were allowed up to
35nt in length to determine the read length. The classiﬁ-
cation of the remaining small RNA sequences was based
on sequence analysis using the provided ﬁlter that removes
known rRNA, tRNA, snRNA, scRNA, repeats and
human endogenous retrovirus elements (HERVs). In this
step, the default ﬁlter provided by SOLiD was used,
allowing up to two mismatches on alignments of 20nt
length. Next, mirBase was used to ﬁlter the known
cellular miRNAs (MirBase version 15). The remaining
small RNA sequences were matched against the human
genome (UCSC hg18). The alignment against the human
genome was performed with the same settings as used in
the alignment against the HIV-1 genome. Matching ﬁles,
generated by the small RNA pipeline, were converted to
‘.gff’ ﬁles using matoGff 0.2.06 (SOLiD software develop-
ment community), which were further examined with
SOLiD Alignment Browser 2.1. Several R scripts
(ShortReads package) were used to plot and connect all
components.
Plasmid and siRNAs construction
To generate vmiRNA expression constructs, the candidate
vmiRNA hairpin domains with  100-bp ﬂanking se-
quences were ampliﬁed from LAI DNA. The primers
encoded the BamHI and XhoI restriction sites for subse-
quent cloning purposes. PCR products were excised from
gel, puriﬁed with the QIAquick gel extraction kit (Qiagen),
BamHI/XhoI digested and cloned in the pcDNA6.2-GW/
EmGFP-miR vector (Invitrogen). These plasmids were
transformed into bacterial TOP10 cells. Positive clones
were selected by colony PCR and sequenced using the
BigDye Terminator v1.1 Cycle Sequencing Kit (Perkin
Elmer Applied Biosystem).
Synthetic vsiRNAs were designed from the HIV-1 anti-
sense reads obtained by SOLiD sequencing. The most
abundant HIV-1 derived antisense reads were selected
and a total of eight vsiRNAs were constructed with the
Silencer siRNA Construction Kit (Ambion) according to
the manufacturer’s instructions. An siRNA targeting the
HIV-1 Nef gene (siNef) was used as positive control, and
an irrelevant siRNA targeting ﬁreﬂy luciferase (siLuc) was
used as a negative control. To inhibit the vsiRNAs, we
designed locked nucleic acids (LNA) molecules that are
perfectly complementary to the vsiRNA (Eurogentec).
Transfection experiments
Human embryonic kidney 293T adherent cells were
grown as monolayer in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% FCS, penicillin (100U/ml) and streptomycin
(100mg/ml) in a humidiﬁed chamber at 37 C and 5%
CO2. Co-transfections of pLAI and the siRNA and/or
LNA were performed in the 96-well format. Per well,
2 10
4 293T cells were seeded in 100ml DMEM with
10% FCS without antibiotics. The next day, 100ng
pLAI (or 25ng pGL-3), 50nM siRNA with or without
50nM LNA, and 0.5ng pRL (Renilla luciferase) were
transfected with 0.5ml Lipofectamine 2000 in 50ml accord-
ing to the manufacturer’s instructions (Invitrogen).
Following transfection of vmiRNA expression con-
structs, 100ng of pLAI (or 25ng of pGL-3) together
with 0, 25 or 100ng of pcDNA6.2-GW/EmGFP-miR
and 0.5ng of pRL (Renilla luciferase) were transfected
with 0.5ml Lipofectamine 2000 in 50ml according to the
manufacturer’s instructions (Invitrogen). Two days after
transfection, the supernatant was harvested, virus was
inactivated and CA-p24 ELISA was performed to
416 Nucleic Acids Research, 2012,Vol. 40,No. 1quantify virus production. The cells were lysed for Renilla
luciferase activity measurements with the Renilla
Luciferase Assay System (Promega). To correct for trans-
fection variation, the CA-p24 values were divided by the
Renilla values. We set the condition that for a valid ex-
periment the ratio between the highest and the lowest
Renilla values should differ by less than a factor of 2.
Transfection experiments were corrected for between
session variations as described previously (22).
Detection of vsiRNA-mediated cleavage by 50-RACE PCR
Human embryonic kidney 293T cells (2 10
6 cells) were
co-transfected with 10 ug of pLAI together with 50nM
vsiRNAs using Lipofectamine 2000 reagent. Total RNA
was extracted 2 days post transfection with the mirVana
miRNA isolation kit (Ambion) according to the manufac-
turer’s protocol. The RNA concentration was measured
using the Nanodrop 1000 (Thermo Fisher Scientiﬁc).
Genomic DNA was removed by DNase treatment using
the TURBO DNA-free kit (Ambion). Of the total RNA,
5mg was used as template in the 50-Rapid Ampliﬁcation of
cDNA Ends (RACE) system (Invitrogen) and the reaction
was carried out according to manufacturer’s protocol.
siRNA detection by northern blotting
Northern blot experiments were performed as previously
described (23). Brieﬂy, human embryonic kidney 293T
cells (5 10
6 cells) were transfected with 40mgo f
shRNA constructs or pLAI using Lipofectamine 2000
reagent. Small RNA was extracted 2 days post transfec-
tion with the mirVana miRNA isolation kit (Ambion,
Austin, TX, USA) according to the manufacturer’s
protocol. The RNA concentration was measured using
the Nanodrop 1000 (Thermo Fisher Scientiﬁc). For
northern blot analysis, 2.4mg small RNA was
electrophoresed in an urea denaturing 15% polyacryl-
amide gel (precast Novex TBU gel, Invitrogen,
Carlsbad, CA, USA). RNA molecular weight markers
(ABI) were prepared as suggested by the manufacturer’s
protocol and run alongside. After electrophoresis, the gels
were stained with 2mg/ml ethidium bromide for 20min
and destained with milliQ water for 10min. The tRNA
signal was visualised under UV light to check for equal
sample loading. The RNA in the gel was electro-
transferred to a positively charged nylon membrane
(Boehringer Mannheim, GmbH, Mannheim, Germany).
The RNA was crosslinked to the membrane using UV
light at a wavelength of 254nm (1200mJ 100).
Hybridizations were performed at 42 C with radiolabeled
locked nucleic acid (LNA) oligonucleotides in 10ml
ULTRAhyb hybridization buffer (Ambion, Austin, TX,
USA) according to the manufacturer’s instructions.
LNA oligonucleotide probes were 50-end labeled with
the kinaseMax kit (Ambion) in the presence of 1ml
[g-
32P] ATP (0.37 MBq/ml Perkin Elmer). To remove un-
incorporated nucleotides, the probes were puriﬁed on
Sephadex G-25 spin columns (Amersham Biosciences) ac-
cording to the manufacturer’s protocol. We used the fol-
lowing vmiRNA-speciﬁc probes (LNA positions
underlined): 50-AAGCAGTGGGTTCCCTAGTTAG-30
(vmiRNA-43/9175) and 50-TGTTTCCCATGTTTCC
TTT-30 (vmiRNA-3270). The signal was detected by auto-
radiography and quantiﬁed using a phosphorimager
(Amersham Biosciences).
RESULTS
Sequencing of small RNAs from HIV-1-infected cells
To study small RNAs in virus-infected mammalian cells,
we infected SupT1 T cells with the primary CXCR4-using
HIV-1 LAI isolate. We performed an acute infection with
relatively high virus input and harvested the cells (60%
infected) at 48h post infection. Uninfected SupT1 cells
served as a negative control. To study the previously
reported vmiRNA encoded by the viral TAR hairpin
motif, SupT1 cells were also infected with the HIV-rtTA
variant. HIV-rtTA is modiﬁed such that Tat-mediated
transcription transactivation is inactivated by mutations
in the TAR hairpin that affect binding of the Tat
protein and the tetO and rtTA components of the
Tet-On system were inserted (24,25). This virus is fully
dependent on doxycycline (dox) for gene expression and
replication and we analyzed parallel infected cultures with
and without dox. Two days post infection total RNA was
isolated from these four cultures, size fractionated
(15–40nt), ligated to adaptors, ampliﬁed by RT–PCR
and sequenced on the SOLiD sequencer. From a single
run, a total of 16127962 raw sequences were analyzed,
resulting in 5210754 identiﬁed small RNAs. Sequences
were categorized as cellular miRNAs, ribosomal RNA,
small nuclear RNA (snRNA), small cytoplasmic RNA
(scRNA), tRNA, LINEs and SINEs (repeats), retrotrans-
poson RNA, other RNAs originating from the human
genome and HIV-1-speciﬁc RNAs. The results obtained
for the HIV-rtTA control infection without dox largely
overlap with the uninfected SupT1 control cells (results
not shown). The distribution among the small RNA
classes for uninfected, HIV-1 and HIV-rtTA-infected
cells is summarized in Figure 2A.
Infected versus non-infected cells: the tRNA
Lys case
Virus-speciﬁc small RNAs were detected in cells infected
with HIV-1 and HIV-rtTA. In the HIV-1-infected cells,
25981 HIV-1-speciﬁc reads (1% of total sequences) were
scored. The HIV-rtTA-infected cells yielded 2474 (0.1%)
virus-speciﬁc reads. HIV-derived small RNA sequences
were up to 33nt long, but most reads were 15–22nt in
length with a peak at around 18nt (Figure 2B, middle
panel). HIV-rtTA yielded a similar pattern (Figure 2B,
lower panel). The analyses of the small RNAs from two
different cultures infected with HIV-1 yielded a similar
small RNA class and size distribution, indicating that
the sequencing method is reproducible (results not
shown). Surprisingly, a HIV-speciﬁc signal with a sharp
peak at 18nt was also detected in the uninfected control
cells (Figure 2B, upper panel). In fact, this ‘HIV-1’ signal
corresponds to a single antisense RNA read that is fully
complementary to the tRNA primer binding site (PBS) of
the HIV-1 RNA genome (Figure 3, lower panel). This
cellular signal was also present in the virus-infected
Nucleic AcidsResearch, 2012, Vol.40,No. 1 417samples. Although this small RNA was previously
reported by Yeung et al. (17) to represent a virus-derived
viRNA, it seems more likely that it represents a degrad-
ation product of the cellular tRNA
Lys3 molecule, which
acts as primer for HIV-1 reverse transcription by anneal-
ing to the complementary PBS (Figure 4A). Several
studies have reported processing of tRNA molecules by
the RNAi machinery (26,27). Further proof for this
scenario comes from the presence of a minor tRNA
Lys5a
fragment that is known to act as minor primer species in
HIV-1 reverse transcription (Figure 4A) (28,29). The 30
terminal 18–21nt of tRNA
Lys3 have a perfect match or
near perfect match (tRNA
Lys5a) with the PBS of HIV-1
RNA (Figure 4B). Thus, the tRNA
Lys3/5a primers explain
the presence of an HIV-like antisense sequence in unin-
fected cells.
Interestingly, the analysis of the tRNA-derived small
RNA fragments suggests that the tRNA primer
concentration is strongly affected by HIV-1 infection
(Figure 4C). The relative number of tRNA
Lys reads is dra-
matically reduced during HIV-1 infection, tRNA
Lys3
drops to 1.4% and tRNA
Lys5a to 4.9% of the respective
pre-infection levels (arbitrarily set at 100%). The level of
all other tRNAs was not as signiﬁcantly affected, which
was plotted for all tRNAs and tRNA
Ala as representative.
A possible explanation for the severe and speciﬁc drop in
tRNA
Lys levels is that these tRNAs are packaged in newly
produced virus particles, although we cannot exclude that
HIV-1 infection selectively blocks the processing of the
tRNA primer species by the RNAi machinery.
HIV-1 plus-strand derived viRNAs
Further analyses of the HIV-derived sequences from
infected cells revealed viRNAs originating primarily
from across the positive-stranded RNA genome
(Figure 3). Only a small portion (1.9%) of the sequences
Figure 2. Distribution of the small RNAs. (A) Small RNA reads obtained after deep-sequencing of uninfected SupT1 cells, SupT1 cells infected with
HIV-1 or HIV-rtTA were annotated. The small RNA reads could be assigned to various RNA classes. The fraction of reads is depicted for each
category. The total number of reads per experimental group is indicated above each chart. (B) Size distribution of HIV-1-derived small RNAs. Small
RNA reads matching HIV-1 or HIV-rtTA sequences were detected by deep-sequencing. The small RNAs vary in size from 15 to 33nt.
The uninfected control was matched against HIV-1 RNA.
418 Nucleic Acids Research, 2012,Vol. 40,No. 1corresponds to the antisense orientation of the HIV-1
RNA, of which the vast majority represents the cellular
tRNA signal. The other antisense reads cluster mostly in
the 30-LTR region of the HIV genome.
We plotted the small RNAs derived from the
plus-strand RNA genome of HIV-1 or HIV-rtTA
against the viral genome map (Figure 3, upper panel).
Close inspection reveals several hot spots of small RNA
production. The most intense peaks marked by a boxed
genome position in Figure 3 were selected for further in-
vestigation. The same overall pattern was observed for
HIV-1 and HIV-rtTA, and we used arrows to align
some identical signals as the HIV-rtTA genome contains
several sequence inserts. There are also some striking dif-
ferences in the small RNA pattern between HIV-1 and
HIV-rtTA, which could be due to the rtTA gene and
tetO insertions or the TAR mutations in the latter virus.
These genome changes may alter the overall genomic
RNA structure, thus leading to different small RNA
products. Please note that the R region, which includes
the TAR element, is identical at both 50 and 30-ends of
the HIV-1 RNA genome. This means that we were
unable to determine the precise origin of the R-derived
small RNA reads and therefore show them at both ends
(Figure 3).
The speciﬁc small RNA products can be produced from
the unspliced or spliced HIV-1 RNAs via Dicer processing
or yet unknown mechanisms. In search for candidate
HIV-1-encoded vmiRNAs, we focused on hotspot RNA
fragments ranging in size from 18 to 21nt. This selection
will remove random RNA degradation products. For the
selected hits, the local RNA secondary structure was
analyzed for the presence of stem–loop structures with
pre-miRNA characteristics. The local RNA structure
was determined by Mfold analyses of the small RNA
with  100nt ﬂanking sequences on each side. This
initial screen revealed 16 candidate pre-vmiRNAs. The
MiPred miRNA prediction software was subsequently
used to obtain a score for each candidate vmiRNA.
MiPred is a computational method for prediction of new
miRNA candidates, which is presented as a percentage of
likelihood (30). Only two candidates passed this stringent
Figure 3. Small RNAs depicted on the HIV-1 RNA genome. The HIV-1 genome is schematically shown in the middle panel. Indicated in green are
the insertions and mutations in HIV-rtTA. The plus-strand small RNAs are depicted in red on top of the HIV-1 genome, and the antisense small
RNA coverage is plotted below in blue. Peaks represent abundant small RNAs. Dotted lines indicate hotspots shared between HIV-1 and HIV-rtTA.
Note that the HIV-rtTA genome is  400nt larger than the HIV-1 genome, explaining the shift seen between identical hot spots. Reads and candidate
viral viRNAs that were investigated in further detail are marked with the boxed genome position. The primer binding site (PBS) on HIV-1 RNA is
indicated in brown and is fully complementary to the major antisense tRNA
Lys-derived read in uninfected and infected cells.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 419test, vmiRNA-43/9175 in the TAR region and
vmiRNA-2413 in the pol gene (Table 1). Hairpin motifs
that do not obtain the threshold score of a real miRNA
are classiﬁed as pseudo-miRNAs: vmiRNA-659, 3270 and
5825. These ﬁve candidate vmiRNAs and their properties
are listed in Table 1 and the predicted pre-vmiRNA
hairpin structures are shown in Figure 5. We noticed a
high level of sequence conservation among HIV-1 strains
for the very likely candidates, vmiRNA-43/9175 and
vmiRNA-2413 (95% and 99%, respectively). Sequence
conservation was determined with the QuickAlign tool
of the Los Alamos HIV sequence database as the percent-
age of 371 HIV-1 subtype B isolates with two or less
mismatches compared to the prototype LAI isolate.
Interestingly, vmiRNA-43/9175 and vmiRNA-659 that
we identiﬁed via the hotspot small RNAs were previously
predicted by computer analyses (31), and the former has
been veriﬁed experimentally (18,24).
Previous studies on vmiRNAs in HIV-1-infected cells
revealed that the TAR hairpin present at the extreme 50
and 30-ends of all HIV-1 transcripts is a substrate for Dicer
and processed into small fragments of miRNA size
(17,33,34). Primarily small RNAs originating from the 30
side of the hairpin were described, which were predicted
to target apoptosis related genes, suggesting that
TAR-derived vmiRNAs may prevent apoptosis of the
infected cell in order to boost virus production (32). We
detected the abundant TAR-derived vmiRNA-43/9175
that is marked in red in the TAR stem–loop models in
Figure 6. Most other RNA fragments were 20–22nt and
originated from the 30 side of the TAR hairpin (Figure 6
and Table 2), in agreement with the previous reports. The
relative accumulation of TAR-derived small RNAs was
signiﬁcantly higher in cells infected with HIV-rtTA than
wild-type HIV-1 (4.3% versus 0.4% of the total HIV-1-
speciﬁc reads). This effect may be due to the multiple
inactivating point mutations present in the TAR motif
of HIV-rtTA (marked in black boxes in Figure 6). These
sequence changes or their structural impact also likely
explains the observed changes in actual TAR-processing
products (Table 2).
Figure 4. tRNA
Lys variants used in HIV-1 reverse transcription. (A) The cloverleaf secondary structure of tRNA
Lys3 and tRNA
Lys5a. The 30-end
sequence that was predominantly sequenced is marked in gray. This region of the tRNA binds to the PBS of HIV-1 RNA. The boxed nucleotides
mark the single base pair difference between the two tRNAs. (B) Both tRNA
Lys molecules can be used as primer for reverse transcription of the
HIV-1 RNA genome. (C) tRNA levels found in HIV-1-infected SupT1 cells and uninfected cells. For tRNA
Lys3 and tRNA
Lys5a, the reads represent
the most abundant short 30-terminal fragment. For all other tRNAs, we tabulated all tRNA-derived fragments of 16–35nt. The number of tRNA
reads was corrected for the number of ribosomal RNAs reads and the values calculated for uninfected cells were set at 100%.
Table 1. HIV-encoded vmiRNA candidates
vmiRNA
candidates
HIV-1
region
No. of
reads
Size
sequence (nt)
G pre-vmiRNA
(kcal/mol)
miRNA score
a (%) Most abundant
sequence
Sequence
conservation
b (%)
References
43/9175 TAR 53 19–22  36.80 Real (78) 43–62 (16 ) 95 (32) (31)
659 gag 175 18–21  18.82 Pseudo (82) 666–685 (55 ) 75 (31)
2413 pol 85 17–23  23.80 Real (60) 2413–2432 (39 ) 99 New
3270 pol 80 17–21  18.20 Pseudo (75) 3274–3292 (38 ) 82 New
5825 env 27 15–21  17.80 Pseudo (66) 5831–5845 (7 ) 92 New
aCalculated by MiPred (30).
bPercentage of strains with  2nt substitutions compared to our prototype LAI.
420 Nucleic Acids Research, 2012,Vol. 40,No. 1Several vmiRNA are processed by the RNAi machinery
To investigate the role of the HIV-1-encoded miRNA can-
didates, we cloned them with 100-nt ﬂanking sequence on
both sides in expression constructs under control of the
CMV promoter. First, the vmiRNAs were tested in
luciferase reporter assays to assess whether the
vmiRNAs can inhibit gene expression in a sequence-
speciﬁc manner (Figure 7A). A speciﬁc luciferase
reporter was constructed for each vmiRNA and its
Figure 5. Secondary structure of candidate HIV-1-encoded pre-vmiRNAs. The number of the pre-miRNA indicates the position on the HIV-1 RNA
genome. The most abundant read scored by deep-sequencing is marked in gray. The RNA structures were predicted by the Mfold algorithm. The
43/9175 pre-vmiRNA represents the 30TAR motif.
Figure 6. Multiple small RNA products are processed from the TAR hairpin. More TAR-derived small RNA reads were obtained from SupT1 cells
infected with HIV-rtTA than HIV-1. The reads are different in sequence, all originating from the 30 arm of the hairpin, but shifting toward the 30-end
of the hairpin for HIV-rtTA. The most abundant sequence is marked in gray in the 30 TAR hairpin for each virus. Mutations within the TAR
hairpin of HIV-rtTA are indicated as black boxed nucleotides.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 421activity in the absence of inhibitor was set at 100%. The
vmiRNA targets, fully complementary to the potentially
processed mature vmiRNA, together with  15nt of the
neighboring sequence was cloned in the 30-UTR of the
luciferase reporter construct. Three of the ﬁve vmiRNAs
showed target inhibition, vmiRNA-659 and 2413 were not
able to knockdown gene expression of their target. All
vmiRNAs were less active than the human miRNA-643
that served as a positive control. These results indicate
that at least three of the HIV-1 vmiRNAs candidates are
processed by the RNAi machinery into functional
miRNAs.
Next, we studied the production of small RNAs from
the candidate vmiRNA constructs. We decided to examine
the small RNA production from the well characterized
TAR hairpin (vmiRNA-43/9175), vmiRNA-659 and
3270. We chose the latter two because they represent a
poorly active (659) and fairly active (3270) vmiRNA.
HEK 293T cells were transfected with the vmiRNA con-
structs or the pLAI HIV-1 genome and we examined small
RNA production by northern blotting. As negative
controls, pBluescript (pBS) and an unrelated vmiRNA
construct were used. Analysis conﬁrmed the processing
of TAR-derived vmiRNA-43/9175 in cells transfected
with the HIV-1 molecular clone (pLAI) and the
vmiRNA-43/9175 expression construct, with a fragment
of  58nt corresponding to the TAR hairpin and a pro-
cessed fragment of  22nt (Figure 7B, left panel). Notably,
the TAR precursor was abundantly present in pLAI-
transfected cells, while almost absent in the vmiRNA-43/
9175 transfected cells. This could be due to the presence of
TAR at both the 50- and 30-ends of the pLAI transcript.
Poorly processive transcription from the viral LTR
promoter may also yield a surplus of short TAR tran-
scripts. Furthermore, the Tat protein is also produced
by pLAI and subsequent binding to TAR may inhibit
Dicer function. In contrast, the vmiRNA-43/9175 tran-
scripts encode only a single TAR structure, the CMV
promoter yields processive transcription complexes and
the Tat protein is not present. These changes may
explain the accumulation of the  22nt small RNA. For
vmiRNA-659, we were not able to detect any small RNA
products (data not shown), which corresponds with the
poor activity in the luciferase assay (Figure 7A). For the
vmiRNA-3270, we observed distinct small RNA products
of  42,  32 and to a lesser extent of  22nt (Figure 7B,
right panel). Although present in extremely small
amounts, the 22nt fragments could represent RNAi pro-
cessing products. Small RNA products were not detected
in pLAI-transfected cells, which could be due to lower
expression from the LTR promoter compared to the
CMV promoter. The vmiRNA-3769 is located in the pol
gene and is thus expressed exclusively in the unspliced
HIV-1 RNA. To test the impact of the vmiRNAs on
HIV-1 production, we co-transfected the vmiRNA con-
structs with the HIV-1 molecular clone pLAI, but no sig-
niﬁcant effect on HIV-1 production was observed (results
not shown). It is possible that the vmiRNAs affect the
expression of cellular mRNAs, which should be addressed
in future studies.
HIV-1 antisense-derived vsiRNAs
Relatively, few sequence reads were found that correspond
to antisense HIV-1 sequences (Figure 3, lower panel).
Similar antisense signals that cluster near the 30-LTR
region were detected in HIV-1 and HIV-rtTA-infected
cells. Interestingly, higher levels of antisense versus sense
RNAs were retrieved from the cells infected with
HIV-rtTA (17.9%) than HIV-1 (1.9%). More than a
quarter of these HIV-rtTA reads originated from the anti-
sense TAR element, which in fact is also likely to adopt a
hairpin structure (35,36). Peaks that map to the R region
are indicated in both the 50R and 30R, but may be derived
from only one of these regions. The majority of 30-end
antisense RNAs are likely to originate from dsRNA
formed between HIV-1 sense and antisense transcripts
that originate from a promoter inside the HIV-1 genome
or a cellular promoter that is located downstream of the
integrated HIV-1 provirus (Figure 1). Such an antisense
promoter is encoded in the genome of several retroviruses
including T-cell lymphotropic virus type 1, feline immuno-
deﬁciency virus, Friend murine leukemia and Moloney
murine leukemia virus (37–41), but also HIV-1 (42,43).
Antisense transcripts from a downstream cellular
promoter have been described for integrated endogenous
retroviral elements (16,44,45). If the latter scenario is true
for HIV-1, the R-derived vsiRNAs are more likely derived
from the 30R.
HIV-1 production is affected by antisense vsiRNA
We hypothesized that the HIV-1-derived antisense se-
quences detected by SOLiD deep sequencing might repre-
sent vsiRNA processing products of dsRNA intermediates
(Figure 1). We selected eight of these antisense fragments
for further analyses (numbered in Figure 3, lower panel).
The corresponding vsiRNAs were generated using in vitro
transcription. In co-transfection experiments with the
pLAI molecular clone, we tested these vsiRNAs for their
ability to inhibit HIV-1 production (Figure 8A). Virus
production was measured as the CA-p24 concentration
in the supernatant and the value obtained in
co-transfection with the control siLuc was set at 100%.
The positive siNef control demonstrated potent inhibition,
but the various vsiRNAs also triggered profound
Table 2. TAR-derived small RNA fragments
Position
a (nt length) HIV-1 HIV-rtTA
37–57 (21) – 23 
38–54 (17) 6  2 
38–58 (21) 7  25 
39–54 (16) 7  –
40–54 (15) – 5 
40–59 (20) – 8 
40–60 (21) 11  28 
b
40–61 (22) – 10 
41–61 (21) 6  –
43–62 (20) 16 
b –
a50R coordinates only.
bMost abundant fragment.
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co-transfection experiments with the pLAI and vsiRNA
7341 and vsiRNA 8200 a 50-RACE PCR was performed to
detect vsiRNA-mediated cleavage of the viral transcript.
In both cases cleavage of the viral transcript was detected
at the position of the vsiRNA. Next, we investigated
whether we could neutralize this effect of the added
vsiRNAs by inhibiting them with antagomirs, e.g.
speciﬁc LNAs (Figure 8B). Antagomir (LNA) 9095 effect-
ively antagonizes the inhibitory effect of vsiRNA 9095
whereas the control LNA molecule that targets an irrele-
vant sequence could not. Virus production without
antagomir and vsiRNA was set at 100%. For the other
four vsiRNAs, we determined the absolute amount of
virus production in the absence and presence of the re-
spective LNAs. The antagomirs could efﬁciently inhibit
the added vsiRNAs, thus increasing virus production.
We next wanted to probe whether inhibitory vsiRNAs
are produced in naturally HIV-infected cells. However,
cells with an integrated HIV-1 provirus cannot easily be
obtained because active virus production leads to massive
cell death. We therefore screened virus production in cells
transfected with pLAI and the vsiRNA antagomirs.
CA-p24 production as measured with the control LNA
molecule was set at 100% (Figure 8C). All vsiRNA-
antagomirs triggered a 2- to 4-fold increase in virus pro-
duction, suggesting that endogenously produced vsiRNAs
restrict HIV-1 gene expression.
DISCUSSION
Ever since the mechanism of RNAi was described as
antiviral mechanism in plants, researchers have addressed
the question whether or not RNAi contributes to the
antiviral defense in other organisms, including mammals.
Figure 7. HIV-1 vmiRNA are functionally active. (A) Expression of vmiRNAs leads to target gene knockdown. 293T cells were co-transfected with
25ng of the respective ﬁreﬂy luciferase reporter plasmid (encoding the vmiRNA target sequence), 0.5ng of renilla luciferase plasmid, and various
amounts of the corresponding vmiRNA constructs. Relative luciferase activity was determined as the ﬁreﬂy to renilla ratio. A scrambled miRNA
(miRNA-scrb) construct served as negative control and the human encoded miRNA-643 was used as positive control. The values measured without
miRNA were set at 100% for each luciferase reporter. (B) Northern blot analysis of the HIV-1-speciﬁc vmiRNAs. Small RNA was isolated from
293T cells transfected with the HIV-1 molecular clone pLAI and the indicated vmiRNA constructs. LNA oligonucleotide probes were used that are
complementary to vmiRNA-43/9175 and 3270. Small RNA isolated from cells transfected with the irrelevant vmiRNA and pBS served as negative
controls.
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eukaryotes and fully functional in mammals, researchers
initially failed to detect the accumulation of short viRNAs
in virus-infected mammalian cells. These viRNAs are con-
sidered the hallmark of antiviral RNAi. To counter the
antiviral RNAi response, plant viruses encode RSSs (46).
These RSSs were shown to suppress antiviral RNAi via
sequestration of antiviral siRNAs, protection of long
virus-speciﬁc dsRNA from processing into siRNAs or
direct inhibition of speciﬁc components of the RNAi
pathway. Despite the lack of viRNA detection in mam-
malian cells, some mammalian viruses do encode RSSs,
which suggests that RNAi also plays a role as antiviral
defense mechanism in mammals (47). Virus-derived
small RNAs are likely rare in mammalian cells due to
the absence of RNA-dependent RNA polymerase that
ampliﬁes siRNA production and thus the antiviral
RNAi response.
The deep-sequencing technology is now enabling a more
sensitive search for those antiviral viRNA molecules. One
of the ﬁrst indications in support of antiviral RNAi in
mammals was the discovery that transposon-speciﬁc
siRNAs, so-called endo-siRNAs, are produced in mouse
oocytes to block transposon activity (16). Because
retroviruses such as HIV-1 are related to endogenous
retrotransposons, it is not unlikely that similar
virus-speciﬁc viRNAs are produced in HIV-1-infected
cells to modulate virus replication and to possibly contrib-
ute to viral latency. viRNAs were recently identiﬁed via
deep sequencing in mammalian cells infected with HIV-1,
Dengue virus, vesicular stomatitis virus, polio virus,
hepatitis C virus and West Nile virus (15,17,18). Small
virus-speciﬁc RNAs appear to accumulate in mamma-
lian-infected cells only to  1%, whereas virus-speciﬁc
RNAs can accumulate to  20% of the total of small
RNA pool in plants (48). This difference in expression
could explain why RNAi has a more signiﬁcant role in
antiviral responses in plants and insects compared to
mammals and that viRNAs are more easily detected in
those organisms. Although viRNAs were detected in
early deep-sequencing studies in infected mammalian
cells, most virus-speciﬁc sequence reads were observed
only once. This greatly reduces the ability to perform
quantitative comparisons. In this study, we used the
latest deep-sequencing technology SOLiD
TM 3 Plus
System to identify HIV-1-derived small RNAs in
infected T cells. Using this extremely sensitive-sequencing
technology, we were able to identify millions of sequence
reads, most of which represent cellular miRNAs. The ex-
pression of some of these cellular miRNAs is strongly
inﬂuenced by HIV-1 infection (Schopman et al, manu-
script in preparation). Importantly, using this technology
Figure 8. Virus production is inhibited by vsiRNAs. (A) 293T cells were co-transfected with 100ng pLAI, 0.5ng renilla luciferase plasmid and 50nM
of the indicated vsiRNA. CA-p24 levels in the culture supernatant were measured and renilla luciferase expression was measured to control for the
transfection efﬁciency. The siRNA targeting ﬁreﬂy luciferase (siLuc) served as negative control to set virus production at 100% and the siRNA
targeting the Nef region of HIV-1 was used as a positive control (siNef). (B) Both vsiRNAs and the corresponding antagomir (LNA) were
co-transfected to investigate whether the antagomirs can antagonize the inhibitory effect of the vsiRNA. Virus production without antagomir or
vsiRNA was set at 100%. An LNA control targeting an irrelevant sequence was used as a negative control. (C) The ability of the LNA antagomirs to
block the endogenous vsiRNAs and to affect virus production was tested. An irrelevant vsiRNA antagomir (ctrl) was used as negative control and
virus production in this setting was arbitrarily set at 100%.
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HIV-1-infected T cell cultures, demonstrating the robust-
ness of this method. Furthermore, similar results were
obtained in preliminary experiments with HIV-1-infected
primary T lymphocytes.
Consistent with previous studies, we detected a small
percentage of the reads (1%) that correspond to
virus-speciﬁc small RNAs (15,17). The majority of these
sequences were found to correspond to the HIV-1
plus-strand RNA, and we reasoned that abundant
species could represent virus-encoded miRNAs,
vmiRNAs. We propose that these small RNAs are pro-
cessed from the viral RNA by Drosha and Dicer
(Figure 1), although we cannot exclude other mechanisms
(e.g. Dicer-mediated cleavage of dsRNA intermediates as
proposed for vsiRNA generation). Mfold and MiPred
analyses of the region encoding these abundant 18–21nt
sequence reads resulted in the identiﬁcation of 5 vmiRNA
candidates, including the previously described TAR
vmiRNA (17,33). Three of these vmiRNAs are functional
in terms of suppressing a luciferase reporter when made
from an expression cassette and 2 vmiRNAs produced
processed  22nt fragments that were detected on
Northern blot. For the TAR vmiRNA we primarily
detected the mature miRNA fragment derived from the
30 side of the TAR hairpin, with some local variation in
the actual cleavage sites. Interestingly, we found that TAR
vmiRNAs were signiﬁcantly overrepresented in cells
infected with the HIV-rtTA variant. The HIV-rtTA
variant contains TAR mutations that prevent Tat
binding, which could enable more efﬁcient recognition of
this hairpin by the Dicer enzyme. The Tat protein has
been shown to suppress RNAi in human cells (33,49,50).
Changes in the TAR hairpin could lead to differences
in processing by Drosha and/or Dicer, thus resulting in
different reads (positions, numbers and length).
Alternatively, exchange of the transcriptional components
of the Tat-TAR system (HIV-1) by those of the Tet-on
system (HIV-rtTA) may lead to non-processive transcrip-
tion, thus increasing the relative concentration of short
50-TAR transcripts. Previous studies showed that HIV-1
can manipulate the host cell RNAi pathway in order to
promote viral latency and/or to suppress antiviral immune
defenses (32,51). We hypothesize that the vmiRNAs
originating from HIV-1 RNA are likely to affect virus
replication in a positive manner. Although our prelimin-
ary results indicated that vmiRNA overexpression does
not signiﬁcantly affect virus production, further detailed
analyses should reveal the biological functions of these
HIV-1-speciﬁc vmiRNAs.
Another interesting ﬁnding was the profound antisense
signal of a speciﬁc 18nt RNA fragment that is fully com-
plementary to the PBS sequence of the HIV-1 RNA
genome. The cellular tRNA
Lys3 molecule binds the PBS
to prime reverse transcription of the HIV-1 RNA genome
into DNA, which can subsequently integrate into the host
genome (29). Yeung et al. (17) were the ﬁrst to report this
speciﬁc small RNA in HIV-1-infected cells and they sug-
gested that it represents a Dicer cleavage product that may
have antiviral activity. However, we detected the same
tRNA-derived small RNA in uninfected control cells.
Therefore, this signal most likely represents processed
tRNA rather than an siRNA processed by Dicer upon
tRNA binding to the PBS. Recent studies have conﬁrmed
that cellular tRNAs can be processed by the RNAi ma-
chinery to yield 18nt 30-terminal fragments in the absence
of virus (26). Whatever the origin, this RNA can poten-
tially target HIV-1 transcripts for degradation by the
RNAi machinery. Further analyses of the tRNA reads
revealed a minor tRNA
Lys5a variant besides the major
tRNA
Lys3 primer species. This ﬁnding conﬁrms previous
biochemical and virological studies and this difference in
efﬁciency of primer usage correlates with the intracellular
concentration of the two tRNA molecules (28,52).
The accumulation of small antisense RNAs is restricted
to the 30-end of the HIV-1 genome. These vsiRNAs are
likely derived from dsRNA intermediates that are pro-
cessed by the RNAi machinery, although we cannot
exclude alternative mechanisms of vsiRNA production.
There are two possible routes for synthesis of such
HIV-1 dsRNA molecules and antisense transcripts.
Morris and co-workers (43) reported that the 30-terminal
part of the HIV-1 DNA genome encodes promoter
activity that could generate antisense HIV-1 transcripts.
Alternatively, the antisense transcripts could be produced
via transcription from a cellular promoter of a neighbor-
ing gene at the site of provirus integration (Figure 1). The
encoded HIV-1 antisense sequences are likely terminated
at the polyadenylation signal in the HIV-1 genome. This
explains why most antisense reads are restricted to the 30
terminal segment. The viral sense and antisense transcripts
could form extended dsRNA, which is a substrate for
Dicer to produce vsiRNAs. We determined that transfec-
tion of in vitro made vsiRNAs transcripts potently inhibits
virus production. Conversely, blocking of the vsiRNAs
made in HIV-1 infected cells with LNA antagomirs
stimulated virus production. We and others previously
identiﬁed HIV-1 Tat to exhibit RSS activity and
reported that Tat-mediated RNAi suppression is
required for optimal virus production (49,50,47,53).
These results are consistent with the notion that RNAi
plays a role in innate antiviral defense and that HIV-1
needs to counter this mechanism. In this study, we
identiﬁed the vsiRNA candidates in HIV-1-infected T
cells that could be involved in the antiviral RNAi
response.
Deep-sequencing technology provides a powerful tool
to unravel the function of small RNAs in cell biology.
Only few studies have used this technology to study
small RNAs in virus-infected cells. Here, we presented
the ﬁrst results of a high-throughput small RNAs-
sequencing project in HIV-1-infected cells. The
combined results suggest that numerous small virus
derived RNAs are produced in HIV-1-infected T cells
that can inﬂuence the viral replication cycle.
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